Erik Dosedla

A new perspective on Endometrial Carcinoma classification and management strategies in context of molecular subtypes

Endometrial cancer is the most common gynecological cancer and the second most prevalent female malignancy in the developed world. It is typically diagnosed in postmenopausal women, presenting with the characteristic clinical symptom of uterine abnormal bleeding. In the past, only two histological types were considered. However, it has become increasingly evident that endometrial cancer is a clinically heterogeneous disease, and this heterogeneity is closely associated with the diversity of underlying molecular alterations. The Cancer Genome Atlas classification has significantly advanced the diagnosis, risk stratification, and management of endometrial cancer by categorizing it into four molecular subgroups, each characterized by distinct mutational burdens and copy number alterations. Key words: endometrial cancer – molecular classification – POLE mutation – The Cancer Genome Atlas Research Network – hysterectomy – targeted therapy – mismatch-repair – p53